Dare Bioscience Inc (NASDAQ:DARE) Q3 2019 Earnings Conference Call - Final Transcript
Nov 14, 2019 • 04:30 pm ET
Welcome to the conference call hosted by Dare Bioscience to review financial results for the quarter ending September 30th, 2019, and to provide a general business update. [Operator Instructions] My name is Sarah, and I will be your operator today.
With us are Sabrina Martucci Johnson, Dare's President and Chief Executive Officer; John Fair, Chief Business Development Officer; and Lisa Walters Hoffert, Dare's Chief Financial Officer.
Ms. Johnson, please proceed.
Sabrina Martucci Johnson
Thank you, and welcome to our financial results and business update call for Dare Bioscience. It's a pleasure to have the opportunity to talk about our third quarter results and our Company highlights and upcoming milestones for the remainder of 2019 and 2020.
Before I begin, I would like to remind you that today's discussion will include forward-looking statements within the meaning of the Federal Securities Laws, which are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements made during this call that are not statements of historical fact should be considered forward-looking statements.Actual results or events could differ materially from those anticipated or implied by these statements due to known and unknown risks and uncertainties. You should not place undue reliance on forward-looking statements.
Forward-looking statements are qualified in their entirety by the cautionary statements in the Company's SEC filings, including our Annual Report on Form 10-K for the year ended December 31st, 2018 and our Quarterly Report on Form 10-Q for the quarter ended September 30, 2019, which was filed on November 12th.
I would also like to point out that the content of this call includes time-sensitive information that is current only as of today, November 14th, 2019. Dare undertakes no obligation to update any forward-looking statements to reflect new information or developments after this call, except as required by law.
Dare is a biopharmaceutical Company squarely focused on improving the life and well-being of women, primarily in the areas of contraception, vaginal health, sexual health and fertility. We continue to deliver on our vision of becoming the premier accelerator of innovation in women's health by advancing our product candidates to meaningful value inflection points and delivering on key program milestones.
On today's call, we will review the two important and exciting updates that we announced earlier this week, the results of our pre-pivotal clinical study of Ovaprene monthly hormone-free vaginal contraceptive candidate and our definitive merger agreement with Microchips Biotech to add an innovative drug delivery platform to our portfolio, with the potential to bring truly game-changing technology to multiple therapeutic areas, including contraception.
After we review these very recent development updates, will spend some time discussing the progress of our late-stage assets, DARE-BV1 and Sildenafil Cream, 3.6% and the upcoming milestones you can expect in the balance of 2019 and 2020.
Let t's start with Ovaprene. We are extremely pleased to be able to share with you the top line findings of our Ovaprene postcoital test clinical trial, a pre-pivotal clinical study. There results are in line